News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Subscribe To Our Newsletter & Stay Updated
